Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Real-World Evidence for Women With Osteoporosis

What Each Drug Actually Does in Your Bones

These two drugs work through entirely different mechanisms, which is why they are not truly interchangeable and why the sequence you use them in matters.

Zoledronic acid binds to hydroxyapatite on bone surfaces and poisons the osteoclast enzyme farnesyl pyrophosphate synthase, halting bone breakdown. One infusion suppresses bone resorption markers for 12 months. Over three years in the HORIZON-Key Fracture Trial, it cut new vertebral fractures by 70%, hip fractures by 41%, and non-vertebral fractures by 25% compared with placebo in postmenopausal women. The drug stays embedded in bone matrix for years after you stop it, which is why a "drug holiday" is an option after three to six infusions for lower-risk women.

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein produced by osteocytes that normally puts the brakes on bone formation. Remove the brake and your own osteoblasts ramp up new bone production while resorption is simultaneously suppressed. The result is a faster and larger bone density gain than any bisphosphonate can achieve. In the ARCH trial, postmenopausal women who received 12 months of romosozumab followed by alendronate had 48% fewer vertebral fractures and 38% fewer clinical fractures over 24 months versus those who received alendronate alone from the start. That difference in fracture reduction is clinically meaningful.

The Dual-Action Window Is Short

Romosozumab's anabolic effect is time-limited to 12 months total. After that window closes, the drug is stopped and you must immediately transition to an antiresorptive agent, typically a bisphosphonate or denosumab, or the bone you gained is partially lost. This is not optional. A structured sequence is the only way to lock in the benefit.

Why Mechanism Matters for Sequencing

If you have been on zoledronic acid for five or more years and your bone density is still very low or you fracture anyway, switching to romosozumab can generate bone that antiresorptive therapy alone cannot. The reverse sequence, going from romosozumab to zoledronic acid, is the one supported by the strongest evidence and is the sequence studied in ARCH.

Head-to-Head Trial Data: What the Evidence Actually Shows

No large randomized trial has directly compared zoledronic acid with romosozumab. Both drugs have been compared against alendronate, which lets you draw an indirect comparison, but there is no HORIZON-vs-ARCH equivalence trial. This evidence gap matters and deserves honesty.

HORIZON-PFT in Detail

The HORIZON-Key Fracture Trial enrolled 7,765 postmenopausal women with osteoporosis (T-score <-2.5 or prior vertebral fracture). At three years, zoledronic acid 5 mg IV yearly reduced:

• Morphometric vertebral fractures: 70% relative risk reduction
• Hip fractures: 41% relative risk reduction
• Non-vertebral fractures: 25% relative risk reduction
• All-cause mortality: 28% reduction (a finding not replicated in the romosozumab trials)

A 2007 mortality signal from HORIZON-PFT remains one of the more striking findings in postmenopausal bone research; zoledronic acid may reduce mortality through mechanisms beyond fracture prevention, though the exact pathway is not established.

ARCH in Detail

The ARCH trial enrolled 4,093 postmenopausal women with osteoporosis and at least one prior vertebral fracture, a higher-risk population than HORIZON. Romosozumab 210 mg SC monthly for 12 months, followed by alendronate, was compared with alendronate alone for 24 months total. Key findings at 24 months:

• New vertebral fractures: 48% lower with romosozumab-to-alendronate vs alendronate-to-alendronate
• Clinical fractures: 27% lower
• Nonvertebral fractures: 19% lower (did not reach statistical significance in some analyses)
• Serious cardiovascular events: 2.5% in the romosozumab group vs 1.9% in the alendronate group

That cardiovascular imbalance in ARCH is the reason romosozumab carries a black-box warning today.

Real-World Evidence: What Happens Outside Controlled Trials

Real-world studies fill in what randomized trials cannot show: persistence, fracture outcomes in diverse women, and what happens when the ideal protocol is not followed. A 2022 analysis from the US MarketScan database found that persistence with zoledronic acid at 24 months was approximately 72% for the full two-dose sequence, substantially better than oral bisphosphonates (roughly 40-50% at two years). Real-world data for romosozumab are still accumulating because the drug only received FDA approval in April 2019, but early registry data from the VERO extension and post-marketing pharmacovigilance confirm that the 12-month anabolic window is frequently cut short in clinical practice when the subsequent antiresorptive is not prescribed promptly, eroding the fracture benefit the drug is designed to deliver.

A framework that WomanRx clinicians use: think of romosozumab as a construction crew that pours the foundation and zoledronic acid as the preservation team that maintains it. You need both, in that order, to build and then keep the bone.

Women-Specific Physiology: How Hormonal Status Changes Everything

Postmenopause: The Core Indication

Both drugs are studied and approved specifically for postmenopausal women with osteoporosis. Estrogen withdrawal accelerates bone resorption; at peak loss in early postmenopause, women can lose 2-3% of spine bone density per year. Zoledronic acid directly counters resorptive acceleration. Romosozumab goes further by simultaneously driving formation, which is why the BMD gains in the spine at 12 months with romosozumab (roughly 13% in the ARCH trial) exceed anything achievable with bisphosphonates alone in the same timeframe.

Perimenopause: Not the Target Population, But Worth Knowing

Neither drug is approved for premenopausal or perimenopausal osteoporosis. If you are in perimenopause with low bone density, ACOG and The Menopause Society position menopausal hormone therapy as the preferred first-line option for bone protection during this window, with bisphosphonates reserved for women who cannot take hormones and who meet a T-score threshold of <-2.5 or have a fragility fracture.

PCOS and Premenopausal Bone Health

Women with PCOS who have had prolonged anovulation or who used high-dose progestins for menstrual suppression may reach menopause with a lower bone reserve than the average woman. This does not change the approved indications, but it does mean your baseline DXA at menopause may reveal more pronounced deficits and an earlier need for pharmacologic therapy.

Female-Pattern Metabolic Disease and Fracture Risk

Type 2 diabetes is underrecognized as a fracture risk factor in women. Research published in JAMA shows that postmenopausal women with type 2 diabetes have higher fracture rates despite having normal or even elevated BMD by DXA, because the bone quality defect in diabetic bone is not captured by standard T-scores. If you have diabetes, FRAX likely underestimates your fracture risk. Both drugs have been used in this population; zoledronic acid has the most data. The Trabecular Bone Score added to DXA can help quantify bone quality independently of density.

Pregnancy, Lactation, and Contraception: Required Reading Before You Start Either Drug

Both zoledronic acid and romosozumab are contraindicated in pregnancy. This is not a theoretical concern: if you are of reproductive age or using either drug before completing menopause, reliable contraception is mandatory.

Zoledronic Acid and Pregnancy

Zoledronic acid is classified as FDA Pregnancy Category D (teratogenic in animal studies; no adequate human data). It accumulates in bone and has a skeletal half-life measured in years. Bisphosphonates cross the placenta and have been associated with neonatal hypocalcemia and skeletal anomalies in case reports. The FDA prescribing information for zoledronic acid advises women of reproductive potential to use effective contraception during treatment and for a period after the last dose; the exact washout period is not established because of the drug's long skeletal retention. If you are planning pregnancy in the next one to two years, discuss the timing of any infusion carefully with your provider.

Lactation: zoledronic acid transfer to breast milk has not been studied in humans. Given the drug's mechanism and the potential for harm to a nursing infant, it should not be used during breastfeeding.

Romosozumab and Pregnancy

Romosozumab is contraindicated in pregnancy. Animal studies showed fetal harm at doses approximating human exposure. FDA prescribing information for romosozumab requires pregnancy testing before initiation and advises effective contraception during treatment. Because the drug is cleared more rapidly than bisphosphonates (serum half-life approximately 6.9 days), there is no prolonged skeletal accumulation concern once dosing stops, but no adequate human pregnancy data exist.

Lactation: romosozumab has not been studied in lactating women. The manufacturer advises against use during breastfeeding. Sclerostin is expressed in breast tissue, and the systemic effects on lactation physiology are unknown.

Fertility Considerations

Neither drug is studied in women trying to conceive. If you are premenopausal with osteoporosis related to a secondary cause (anorexia, celiac disease, glucocorticoid use) and you are planning pregnancy, your bone specialist and reproductive endocrinologist need to coordinate timing. Calcium 1,000-1,200 mg/day and vitamin D 1,500-2,000 IU/day are the only bone treatments with an acceptable safety profile throughout pregnancy and lactation.

Who This Treatment Is Right For (and Who Should Choose Differently)

Zoledronic Acid Is Likely the Better Fit If:

• You have been diagnosed with postmenopausal osteoporosis (T-score <-2.5) without a prior major fragility fracture
• You find oral bisphosphonate adherence difficult due to GI side effects or the fasting requirements
• Your FRAX 10-year hip fracture probability is >3% or major osteoporotic fracture probability is >20%
• Your creatinine clearance is >35 mL/min (the minimum threshold for safe infusion)
• Cost and insurance coverage are a priority: Reclast has generic options and is typically covered without step therapy
• You want a once-yearly infusion and value long-term safety data spanning 15+ years

Romosozumab Is Likely the Better Fit If:

• You have already had one or more fragility fractures (vertebral or hip) and are classified as "very high risk" by AACE/ACE 2020 guidelines
• You have been on antiresorptive therapy for several years and continue to fracture or have very low T-scores (below -3.0)
• Your treating clinician has confirmed no prior MI or stroke in the past 12 months (the cardiovascular black-box warning requires this screen)
• You are willing to commit to 12 monthly injections followed immediately by a bisphosphonate or denosumab
• Your insurer has approved it after prior authorization (romosozumab typically requires documented failure or contraindication to a bisphosphonate at most US plans)

Who Should Not Use Romosozumab:

Women with a history of MI or stroke should not receive romosozumab. This is the clearest prescribing boundary the ARCH data established. It is not a relative caution; it is a labeled contraindication. If your cardiovascular history includes either event, zoledronic acid, denosumab, or teriparatide is the appropriate path.

Kidney Function Is the Limiting Factor for Zoledronic Acid

Zoledronic acid is renally cleared. It is contraindicated when creatinine clearance is <35 mL/min. As kidney function declines with age, this threshold becomes clinically relevant for many women in their 70s and 80s. Romosozumab does not require dose adjustment for kidney function and is a reasonable alternative in women with moderate CKD who are at very high fracture risk, though data in advanced CKD (stages 4-5) are limited.

Switching From Reclast to Evenity: What You Need to Know

Switching from zoledronic acid to romosozumab is a real clinical scenario, typically considered when a woman has been on bisphosphonate therapy for three to five years, has had a drug holiday, and then sustains a new fracture, or when her bone density has not responded adequately. Here is what the evidence and guidelines say about this switch.

The Evidence for Switching

The ARCH trial included women who had prior bisphosphonate exposure (approximately 30% of the enrolled population had received prior alendronate). Among those with prior bisphosphonate use, romosozumab still produced meaningful BMD gains, though the absolute increment was somewhat smaller than in bisphosphonate-naive women. There is no large randomized trial specifically studying prior zoledronic acid users switching to romosozumab; the data are extrapolated from ARCH subgroup analyses and smaller registry studies.

A 2021 retrospective analysis published in Osteoporosis International found that women switching from bisphosphonates to romosozumab after a new clinical fracture achieved spine BMD gains of approximately 9.8% at 12 months, compared with 12.8% in bisphosphonate-naive women starting romosozumab, a difference that is meaningful but not prohibitive.

Timing the Switch

No mandatory washout period is required before starting romosozumab after zoledronic acid. In practice, most clinicians initiate romosozumab at the point when the next annual zoledronic acid infusion would have been due. Bone turnover markers (serum P1NP for formation, CTX for resorption) can help confirm that residual bisphosphonate suppression has not completely eliminated the anabolic signal. If CTX is very low (<100 ng/L), some specialists prefer to wait until turnover markers partially recover before starting romosozumab, though this approach has not been tested in a randomized trial.

After Romosozumab: Going Back to Zoledronic Acid

After 12 months of romosozumab, returning to zoledronic acid annually for two to three additional years is the most common and well-supported consolidation strategy. The FRAME and ARCH trial extensions confirm that bisphosphonate consolidation maintains the bone gained during the anabolic phase. Losing this consolidation step, by not receiving the follow-up infusion within three to four months of the last romosozumab injection, can result in partial reversal of the BMD gains.

Monitoring, Side Effects, and Practical Differences

Acute Phase Reaction: Zoledronic Acid's Most Common Side Effect

Approximately 30% of women experience a flu-like reaction within 24 to 72 hours of their first zoledronic acid infusion: fever, myalgia, headache, and bone pain. This acute phase reaction is driven by gamma-delta T-cell activation and is substantially less common with the second and subsequent infusions. Pre-hydrating with 500 mL of fluid before the infusion and taking acetaminophen 500-1,000 mg every six hours for 24 hours after the infusion reduces severity. Research from the HORIZON trial showed the reaction occurred in 31.6% of zoledronic acid recipients after the first dose versus 6.2% after placebo.

Jaw and Bone Concerns Common to Both Drugs

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are rare but real risks with prolonged antiresorptive therapy. ONJ risk with zoledronic acid in osteoporosis doses is approximately 1 in 10,000 to 1 in 100,000 patient-years, far lower than the risk seen with cancer-dose bisphosphonates. Dental examination and completion of any invasive dental work before starting either drug is standard practice. Romosozumab also carries a small ONJ risk, primarily relevant when transitioning to or from antiresorptive agents.

Injection Site Reactions: Romosozumab

Romosozumab requires two subcutaneous injections (each 105 mg, for a total of 210 mg) monthly at separate sites. Injection site reactions occur in approximately 5% of women and are generally mild. The monthly schedule requires commitment; missing doses disrupts the anabolic window.

Calcium and Vitamin D Are Not Optional

Both drugs require adequate calcium and vitamin D before and during treatment. Hypocalcemia after zoledronic acid infusion can be severe if vitamin D deficiency is not corrected first. The Menopause Society recommends 1,200 mg/day of calcium (from food and supplements combined) and 800-1,000 IU/day of vitamin D for postmenopausal women; many bone specialists target 25-hydroxyvitamin D levels above 30 ng/mL before any infusion or injection.

A Practical Decision Map for Your Appointment

When you sit down with your clinician to choose between these two drugs, the conversation should cover five questions in order:

1. What is your T-score at the spine and hip, and have you had a prior fragility fracture? A T-score below -3.0 or any prior hip or vertebral fracture moves you toward romosozumab consideration.
2. What is your cardiovascular history? Any MI or stroke within the past 12 months rules out romosozumab.
3. What is your creatinine clearance? Below 35 mL/min rules out zoledronic acid.
4. What is your FRAX 10-year fracture probability? The NOF/BHOF guidelines recommend pharmacologic treatment when 10-year hip fracture probability is >3% or major osteoporotic fracture probability is >20%.
5. What antiresorptive will follow romosozumab if you start it? If that follow-up plan is not in place before the first injection, the drug should not be started.